Literature DB >> 28131320

Incidence and Management of Restenosis After Treatment of Unprotected Left Main Disease With Second-Generation Drug-Eluting Stents (from Failure in Left Main Study With 2nd Generation Stents-Cardiogroup III Study).

Fabrizio D'Ascenzo1, Alaide Chieffo2, Enrico Cerrato3, Fabrizio Ugo4, Marco Pavani5, Hyroishi Kawamoto2, Roberto di Summa5, Ferdinando Varbella3, Giacomo Boccuzzi4, Pierluigi Omedè5, Sara Rettegno5, Roberto Garbo4, Federico Conrotto5, Antonio Montefusco5, Giuseppe Biondi-Zoccai6, Maurizio D'Amico5, Claudio Moretti5, Javier Escaned7, Fiorenzo Gaita5, Antonio Colombo2.   

Abstract

Incidence, predictors, and impact on prognosis of target lesion revascularization (TLR) for patients treated with second-generation drug-eluting stents (DESs) on unprotected left main (ULM) remain to be defined. The present study is a multicenter study including patients treated with a second-generation DES on ULM from June 2007 to January 2015. Rate of TLR was the primary end point. All cause death, myocardial infarction, target vessel revascularization, and stent thrombosis were the secondary end points. A total of 1,270 patients were enrolled: after a follow-up of 650 days (230 to 1,170), 47 (3.7%) of them underwent a re-percutaneous coronary intervention TLR on the left main, 22 during a planned angiographic follow-up. Extent of coronary artery disease was similar among groups (median value of Syntax of 27 ± 10 vs 26 ± 9, p = 0.45), as localization of the lesion in the ULM. Of patients reporting with TLR on ULM, 56% presented with a focal restenosis, 33% diffuse and 10% proliferative. At multivariate analysis, insulin-dependent diabetes mellitus increased risk of TLR (hazard ratio [HR] 2.0: 1.1 to 3.6, p = 0.04), whereas use of intravascular ultrasound resulted protective (HR 0.5: 0.3 to 0.9, p = 0.02). At follow-up, rates of cardiovascular death did not differ among the 2 groups (4% vs 4%, p = 0.95). At multivariate analysis, TLR on LM did not increase risk of all cause death (HR 0.4: 0.1 to 1.6, p = 0.22), whereas cardiogenic shock and III tertile of Syntax portended a worse prognosis (HR 4.5: 2.1 to 10.2, p = 0.01 and HR 1.4: 1.1 to 1.6, p = 0.03, respectively). In conclusion, repeated revascularization after implantation of second-generation DES on ULM represents an unfrequent event, being increased in insulin-dependent patients and reduced by intravascular ultrasound. Impact on prognosis remains neutral, being related to clinical presentation and extent of coronary artery disease.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28131320     DOI: 10.1016/j.amjcard.2016.12.005

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

Review 1.  Assessing Prognosis of Acute Coronary Syndrome in Recent Clinical Trials: A Systematic Review.

Authors:  Fan Ye; David Winchester; Michael Jansen; Arthur Lee; Burton Silverstein; Carolyn Stalvey; Matheen Khuddus; Joseph Mazza; Steven Yale
Journal:  Clin Med Res       Date:  2019-06

2.  Prediction of All-Cause Mortality Following Percutaneous Coronary Intervention in Bifurcation Lesions Using Machine Learning Algorithms.

Authors:  Jacopo Burrello; Guglielmo Gallone; Alessio Burrello; Daniele Jahier Pagliari; Eline H Ploumen; Mario Iannaccone; Leonardo De Luca; Paolo Zocca; Giuseppe Patti; Enrico Cerrato; Wojciech Wojakowski; Giuseppe Venuti; Ovidio De Filippo; Alessio Mattesini; Nicola Ryan; Gérard Helft; Saverio Muscoli; Jing Kan; Imad Sheiban; Radoslaw Parma; Daniela Trabattoni; Massimo Giammaria; Alessandra Truffa; Francesco Piroli; Yoichi Imori; Bernardo Cortese; Pierluigi Omedè; Federico Conrotto; Shao-Liang Chen; Javier Escaned; Rosaly A Buiten; Clemens Von Birgelen; Paolo Mulatero; Gaetano Maria De Ferrari; Silvia Monticone; Fabrizio D'Ascenzo
Journal:  J Pers Med       Date:  2022-06-17

3.  Percutaneous Coronary Intervention vs. Coronary Artery Bypass Grafting for Treating In-Stent Restenosis in Unprotected-Left Main: LM-DRAGON-Registry.

Authors:  Wojciech Wańha; Jacek Bil; Michalina Kołodziejczak; Adam Kowalówka; Mariusz Kowalewski; Damian Hudziak; Radosław Gocoł; Rafał Januszek; Tomasz Figatowski; Marek Milewski; Brunon Tomasiewicz; Piotr Kübler; Bruno Hrymniak; Piotr Desperak; Łukasz Kuźma; Krzysztof Milewski; Bartłomiej Góra; Andrzej Łoś; Jan Kulczycki; Adrian Włodarczak; Wojciech Skorupski; Marek Grygier; Maciej Lesiak; Fabrizio D'Ascenzo; Marek Andres; Paweł Kleczynski; Radosław Litwinowicz; Andrea Borin; Grzegorz Smolka; Krzysztof Reczuch; Marcin Gruchała; Robert J Gil; Miłosz Jaguszewski; Krzysztof Bartuś; Piotr Suwalski; Sławomir Dobrzycki; Dariusz Dudek; Stanisław Bartuś; Mariusz Ga Sior; Andrzej Ochała; Alexandra J Lansky; Marek Deja; Jacek Legutko; Elvin Kedhi; Wojciech Wojakowski
Journal:  Front Cardiovasc Med       Date:  2022-04-29

4.  Effects of Cilostazol-Based Triple Antiplatelet Therapy Versus Dual Antiplatelet Therapy After Coronary Drug-Eluting Stent Implantation: An Updated Meta-Analysis of the Randomized Controlled Trials.

Authors:  Shijie Zhao; Zhaoshuang Zhong; Guoxian Qi; Liye Shi; Wen Tian
Journal:  Clin Drug Investig       Date:  2019-01       Impact factor: 2.859

Review 5.  Diabetes and restenosis.

Authors:  Scott Wilson; Pasquale Mone; Urna Kansakar; Stanislovas S Jankauskas; Kwame Donkor; Ayobami Adebayo; Fahimeh Varzideh; Michael Eacobacci; Jessica Gambardella; Angela Lombardi; Gaetano Santulli
Journal:  Cardiovasc Diabetol       Date:  2022-02-14       Impact factor: 9.951

6.  Comparison of bioresorbable vs durable polymer drug-eluting stents in unprotected left main (from the RAIN-CARDIOGROUP VII Study).

Authors:  Mario Iannaccone; Umberto Barbero; Michele De Benedictis; Yoichi Imori; Giorgio Quadri; Daniela Trabattoni; Nicola Ryan; Giuseppe Venuti; Andrea Montabone; Wojciech Wojakowski; Andrea Rognoni; Gerard Helft; Radoslaw Parma; Leonardo De Luca; Michele Autelli; Giacomo Boccuzzi; Alessio Mattesini; Christian Templin; Enrico Cerrato; Wojciech Wańha; Grzegorz Smolka; Zenon Huczek; Francesco Tomassini; Bernardo Cortese; Davide Capodanno; Alaide Chieffo; Ivan Nuñez-Gil; Sebastiano Gili; Antonia Bassignana; Carlo di Mario; Baldassarre Doronzo; Pierluigi Omedè; Maurizio D'Amico; Delio Tedeschi; Ferdinando Varbella; Thomas Luscher; Imad Sheiban; Javier Escaned; Mauro Rinaldi; Fabrizio D'Ascenzo
Journal:  BMC Cardiovasc Disord       Date:  2020-05-15       Impact factor: 2.298

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.